Delayed esophageal anastomotic complication and ramucirumab therapy: A case report

Current NCCN guidelines for second‐line therapy in recurrent or metastatic esophago‐gastric cancers recommend the use of VEGF inhibitors such as ramucirumab. VEGF inhibitors have been shown to be associated with gastrointestinal perforation in clinical trials and late colorectal anastomotic leaks in...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Robert H., Malfitano, Madison J., Reilley, Matthew, Martin, Linda W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569901/
https://www.ncbi.nlm.nih.gov/pubmed/37667428
http://dx.doi.org/10.1111/1759-7714.15084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569901/
https://www.ncbi.nlm.nih.gov/pubmed/37667428
http://dx.doi.org/10.1111/1759-7714.15084

Ejemplares similares